Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment

被引:3
|
作者
Speth, Cornelia [1 ]
Bellotti, Ruben [2 ]
Schaefer, Georg [3 ]
Rambach, Gunter [1 ]
Texler, Bernhard [2 ]
Thurner, Gudrun C. [3 ]
Oefner, Dietmar [2 ]
Lass-Floerl, Cornelia [1 ]
Maglione, Manuel [2 ]
机构
[1] Med Univ Innsbruck, Inst Hyg & Med Microbiol, A-6020 Innsbruck, Austria
[2] Med Univ Innsbruck, Dept Visceral Transplant & Thorac Surg, A-6020 Innsbruck, Austria
[3] Med Univ Innsbruck, Inst Pathol Neuropathol & Mol Pathol, A-6020 Innsbruck, Austria
关键词
tumorigenesis; mycobioma; complement; pancreas; tumor marker; Malassezia; fungal dysbiosis; PANCREATIC DUCTAL ADENOCARCINOMA; ANAPHYLATOXIN C5A; STELLATE CELLS; CANCER; ACTIVATION; EXPRESSION; REGULATORS; PATHWAY; IDENTIFICATION; BIOMARKER;
D O I
10.3390/curroncol29120773
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is still hampered by a dismal prognosis. A better understanding of the tumor microenvironment within the pancreas and of the factors affecting its composition is of utmost importance for developing new diagnostic and treatment tools. In this context, the complement system plays a prominent role. Not only has it been shown to shape a T cell-mediated immune response, but it also directly affects proliferation and apoptosis of the tumor cells, influencing angiogenesis, metastatic spread and therapeutic resistance. This makes complement proteins appealing not only as early biomarkers of PDAC development, but also as therapeutic targets. Fungal dysbiosis is currently the new kid on the block in tumorigenesis with cancer-associated mycobiomes extracted from several cancer types. For PDAC, colonization with the yeast Malassezia seems to promote cancer progression, already in precursor lesions. One responsible mechanism appears to be complement activation via the lectin pathway. In the present article, we review the role of the complement system in tumorigenesis, presenting observations that propose it as the missing link between fungal dysbiosis and PDAC development. We also present the results of a small pilot study supporting the crucial interplay between the complement system and Malassezia colonization in PDAC pathogenesis.
引用
收藏
页码:9833 / 9854
页数:22
相关论文
共 50 条
  • [1] Mycobiome dysbiosis and complement activation as putative players in PDAC progression
    Speth, C.
    Faserl, J.
    Neurauter, M.
    Bellotti, R.
    Rambach, G.
    Hube, B.
    Schafer, G.
    Ofner, D.
    Lass-Florl, C.
    Maglione, M.
    MYCOSES, 2022, 65 : 15 - 16
  • [2] Potential Diagnostic and Prognostic Complement Markers in Head and Neck Cancer
    Schaefer, Nicole
    Heimer, Sina Franziska
    Vlasow, Denis
    Schmidt, Lisa Marie
    EttI, Tobias
    Bauer, Richard Josef
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 116 - 116
  • [3] Complement components as potential therapeutic targets for asthma treatment
    Khan, Mohammad Afzal
    Nicolls, Mark R.
    Surguladze, Besiki
    Saadoun, Ismail
    RESPIRATORY MEDICINE, 2014, 108 (04) : 543 - 549
  • [4] Identifying and validating PLAU as a potential prognostic biomarker for PDAC
    Peng An
    Junhong Wang
    Rong Fan
    Scientific Reports, 15 (1)
  • [5] Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers
    Laderach, Diego J.
    Gentilini, Lucas
    Jaworski, Felipe M.
    Compagno, Daniel
    PROSTATE CANCER, 2013, 2013
  • [6] Determination of Potential Therapeutic Targets and Prognostic Markers of Ovarian Cancer by Bioinformatics Analysis
    Zhang, Jing
    Huang, Shouguo
    Quan, Lini
    Meng, Qiu
    Wang, Haiyan
    Wang, Jie
    Chen, Jin
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [7] MicroRNAs Associated With Colon Cancer: New Potential Prognostic Markers and Targets for Therapy
    Zhu, Junfeng
    Xu, Ying
    Liu, Shanshan
    Qiao, Li
    Sun, Jianqiang
    Zhao, Qi
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2020, 8
  • [8] Potential biofluid markers and treatment targets for renal cell carcinoma
    Wettersten, Hiromi I.
    Weiss, Robert H.
    NATURE REVIEWS UROLOGY, 2013, 10 (06) : 336 - 344
  • [9] Potential biofluid markers and treatment targets for renal cell carcinoma
    Hiromi I. Wettersten
    Robert H. Weiss
    Nature Reviews Urology, 2013, 10 : 336 - 344
  • [10] AHNAK2 is a potential prognostic biomarker in patients with PDAC
    Lu, Di
    Wang, Junxiong
    Shi, Xiaoyan
    Yue, Bing
    Hao, Jianyu
    ONCOTARGET, 2017, 8 (19) : 31788 - 31797